SAP proposes increased dividend for fiscal year 2025

Dr. h. c. mult. Pekka Ala-Pietilae Chairman of the Supervisory Board SAP SE SAP SE
Dr. h. c. mult. Pekka Ala-Pietilae Chairman of the Supervisory Board SAP SE - SAP SE
0Comments

SAP SE has announced that its Supervisory Board and Executive Board are recommending a dividend of €2.50 per share for the 2025 fiscal year, an increase of €0.15 or 6.4% compared to the previous year.

If shareholders approve this proposal and assuming the number of treasury shares remains unchanged as of December 31, 2025, SAP estimates that the total dividend payout will be about €2.919 billion, up from €2.743 billion in 2024. This represents a pay-out ratio of 40.7%, compared to 52% in the prior year.

The company stated: “SAP believes that its shareholders should benefit appropriately from the profit the Company made in 2025. The Company’s dividend policy is to pay a dividend totaling 40% or more of Non-IFRS profit after tax.”

Key dates related to this proposed dividend include May 5, 2026 as the record date for payment eligibility, May 6 as the ex-dividend date, and May 8 as the payment date.

For holders of SAP American Depositary Receipts (ADRs), each ADR corresponds to one SAP SE share. The final amount received per ADR will depend on euro/U.S. dollar exchange rates at the time of payment. While dividends are paid out in euros on ordinary shares by SAP SE, currency fluctuations will impact U.S.-dollar payments for ADR holders.

SAP describes itself as a global leader in enterprise applications and business AI with more than five decades supporting organizations across various sectors including finance, procurement, HR, supply chain management, and customer experience.

Further information for investors is available via Alexandra Steiger at [email protected] or through SAP Investor Relations on LinkedIn; media contacts include Marcus Winkler and Daniel Reinhardt.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.